TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6164204
Drug: Dihydroergotamin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamin and low-dose heparin (DHEH)
Study: 31404668
Drug: Reslizumab 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reslizumab 3.0 mg/kg (more than 12 months exposure)
Study: 25392071
Drug: Atorvastatin (n=255)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (n=255)
Study: 12955096
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg octreotide administered subcutaneously at 2245
Study: 26402918
Drug: LCZ696 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 200 mg, increased to 400 mg if uncontrolled after 2 weeks, with optional addition of another antihypertensive drug after 4 weeks (n=21)
Study: 24821628
Drug: L-bent-level gesture
Normalized name: colonial bent grass pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-bent-level gesture
Study: 18594000
Drug: nab-paclitaxel (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel (260 mg/m² as a 30-minute infusion)
Study: 18594000
Drug: sb-paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: sb-paclitaxel (175 mg/m² as a 3-hour infusion)
Study: 7721556
Drug: Daily baths
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily baths in the Dead Sea (Group 1, n = 9)
Study: 7721556
Drug: Daily sulphur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sulphur baths (Group 2, n = 9)
Study: 7721556
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of daily Dead Sea bathing and sulphur baths (Group 3, n = 10)
Study: 30378759
Drug: PLGM threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLGM threshold at 90 mg/dL during exercise
Study: 30378759
Drug: PLGM threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLGM threshold at 70 mg/dL during exercise
Study: 15608053
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (zidovudine/lamivudine and efavirenz)
Study: 15608053
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (zidovudine/lamivudine/abacavir and efavirenz)
Study: 2108751
Drug: Erythropoietin to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin to achieve a haemoglobin concentration of 95‐110 g/l (n = 40)
Study: 2108751
Drug: Erythropoietin to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin to achieve a haemoglobin concentration of 115‐130 g/l (n = 38)
Study: 7352279
Drug: Buprenorphine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (4 mg/day)
Study: 28235249
Drug: Secukinumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (both doses)
Study: 21561791
Drug: Intermittent androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent androgen deprivation therapy (IAD)
Study: 21561791
Drug: Continuous androgen
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous androgen deprivation therapy (CAD)
Study: 25622671
Drug: 0.50 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 µg calcitriol daily
Study: 25622671
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (original treatment regimen)
Study: 12833245
Drug: Intravenous pulses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pulses of methylprednisolone (MEP)
Study: 12833245
Drug: Gold standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold standard dose of 1 g/day for 3 consecutive days of MEP
Study: 12833245
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of MEP
Study: 10036892
Drug: Propofol injected
Normalized name: propofol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol injected through a peripheral cannula without carrier intravenous fluid (group B, n = 13)
Study: 10036892
Drug: Propofol injected
Normalized name: propofol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol injected through a peripheral cannula with rapid infusion of acetated Ringer's solution (group C, n = 13)
Study: 10036892
Drug: Propofol injected
Normalized name: propofol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol injected through a peripheral cannula without carrier intravenous fluid (group B)
Study: 10036892
Drug: Propofol injected
Normalized name: propofol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol injected through a peripheral cannula with rapid infusion of acetated Ringer's solution (group C)
Study: 8694599
Drug: Heparin-bonded circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded circuits (HBC) with lower anticoagulation therapy (activated clotting time > 280 seconds)
Study: 8694599
Drug: Heparin-bonded circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded circuits (HBC) with lower anticoagulation therapy
Study: 8694599
Drug: Conventional, nonheparin-bonded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional, nonheparin-bonded circuits with full anticoagulation therapy (activated clotting time > 480 seconds)
Study: 1831686
Drug: Daily supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supervised toothbrushing with three-monthly scale and polish and reinforcement of oral hygiene instruction (Group 3)
Study: 1831686
Drug: Daily supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supervised toothbrushing with one-monthly input from a dental hygienist (Group 4)
Study: 1831686
Drug: Daily supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supervised toothbrushing without additional treatment (Control group)
Study: 1831686
Drug: Daily supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supervised toothbrushing with three-monthly scale and polish (Group 3)
Study: 7159690
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet containing 25 mg bemetizide and 50 mg triamterene
Study: 7159690
Drug: Bemetizide alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemetizide alone (25 mg)
Study: 7159690
Drug: Triamterene alone
Normalized name: Triamterene
DrugBank: Triamterene (DB00384)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamterene alone (50 mg)
Study: 31033867
Drug: Sodium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium intake of 2,400 mg per day
Study: 31033867
Drug: Sodium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium intake of 1,500 mg per day
Study: 26010521
Drug: 21‐mg transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21‐mg transdermal nicotine patch
Study: 22015074
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (30-minute intravenous infusion)
Study: 18091545
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with meropenem (1 g every 8 hrs) and ciprofloxacin (400 mg every 12 hrs)
Study: 18091545
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with meropenem alone
Study: 8203833
Drug: Cefepime (CP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (CP; 2.0 g IV every 12 h)
Study: 8203833
Drug: Ceftazidime (CZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (CZ; 2.0 g IV every 8 h)
Study: 31863557
Drug: Metformin (1450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1450 ± 550 mg/day)
Study: 1396725
Drug: Cefuroxime 750
Normalized name: cefuroxime 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 750 mg t.i.d. followed by oral cefuroxime axetil 500 mg b.i.d.
Study: 1396725
Drug: Amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin plus clavulanic acid (1.2 g intravenously t.i.d. followed by 625 mg orally t.i.d.)
Study: 1396725
Drug: Amoxicillin/CA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/CA
Study: 3091097
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day methylene blue
Study: 3091097
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day methylene blue (control)
Study: 30532527
Drug: Calcitriol 0.5
Normalized name: CALCITRIOL 0.5MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 0.5 µg/day
Study: 24277915
Drug: Silirum vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silirum vaccine
Study: 22176900
Drug: Yinzhihuang oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yinzhihuang oral liquid combined with phototherapy
Study: 18831071
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (PASCET-PI)
Study: 17571600
Drug: Milrinone (M
Normalized name: Product containing milrinone (medicinal product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (M group) administered continuously at a rate of 0.15‐0.30 microg x kg(‐1) min(‐1) after sternotomy until the end of operation.
Study: 15257113
Drug: Medication NR
Normalized name: carbinoxamine maleate Oral Solution [Cordron NR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication NR
Study: 15257113
Drug: Medication RES
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication RES
Study: 11448916
Drug: Antiangiogenic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiangiogenic therapy with razoxane
Study: 8064281
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with radiation therapy
Study: 8064281
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy alone (Control)
Study: 4951240
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg fentanyl intramuscularly
Study: 4951240
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg morphine intramuscularly
Study: 27171508
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg once daily (monotherapy)
Study: 27171508
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg once daily (add-on to metformin)
Study: 27171508
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg once daily (add-on to pioglitazone)
Study: 27171508
Drug: Alogliptin (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin (any treatment group)
Study: 25511300
Drug: NaF solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF solution at pH4.5
Study: 25511300
Drug: NaF solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaF solution at pH7.0
Study: 22069045
Drug: PEG‐IFNα‐2b plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFNα‐2b plus lamivudine 100 mg/d
Study: 22069045
Drug: PEG‐IFNα‐2b 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFNα‐2b 1.5 µg/kg o. i. w.
Study: 12196081
Drug: Fondaparinux (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux (2.5 mg, once daily, starting 6 hours after surgery)
Study: 9706946
Drug: Cisatracurium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.25 mg/kg
Study: 10527226
Drug: Vecuronium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.15 mg/kg
Study: 389838
Drug: Indomethacin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (3 x 25 mg/day)
Study: 389838
Drug: Combined indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined indomethacin + sodium-salicylate (3 x 25 mg/day and 3 x 250 mg/day)
Study: 19830413
Drug: Pummelo juice
Normalized name: pummelo extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pummelo juice with 50 mg sildenafil
Study: 19830413
Drug: Water with
Normalized name: sterile water with electrolytes injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water with 50 mg sildenafil
Study: 14763193
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of quinacrine at each cornual angle (3 double insertions, a month apart)
Study: 14763193
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of quinacrine at each cornual angle (single double insertion)
Study: 14763193
Drug: 252 mg
Normalized name: menthol 0.0252 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 252 mg to 360 mg of quinacrine (2 insertions, a month apart, fundal placement)
Study: 11030470
Drug: Nateglinide 120
Normalized name: nateglinide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 120 mg 3 times daily before meals
Study: 11030470
Drug: Nateglinide 120
Normalized name: nateglinide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 120 mg plus metformin 500 mg, both 3 times daily
Study: 11030470
Drug: Nateglinide 60
Normalized name: nateglinide 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 60 or 120 mg 3 times daily plus metformin 1 g twice daily
Study: 11030470
Drug: Nateglinide 120
Normalized name: nateglinide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 120 mg 3 times daily
Study: 11030470
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with troglitazone 600 mg daily
Study: 8654613
Drug: All patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients after chemotherapy
Study: 1794820
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution (controls) in the anterior chamber
Study: 6212962
Drug: Amitriptyline 75
Normalized name: amitriptyline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 75 mg + Ethanol 50 g
Study: 6212962
Drug: Zimelidine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine 200 mg + Ethanol 50 g
Study: 6212962
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Ethanol 50 g
Study: 30106333
Drug: No desensitizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: No desensitizer treatment
Study: 26499112
Drug: 1.8 ml
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 ml of 0.5% hyperbaric bupivacaine at 5 °C (group I, n = 50)
Study: 26499112
Drug: 1.8 ml
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 ml of 0.5% hyperbaric bupivacaine at 23 °C (group II, n = 50)
Study: 12542209
Drug: Caroverine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caroverine (120 mg/day for 4 weeks)
Study: 12542209
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (400 mg/day for 4 weeks)
Study: 2535284
Drug: Bupivacaine/methylprednisolone solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine/methylprednisolone solution (22 ml) injected over 2 minutes in horizontal position
Study: 2535284
Drug: Bupivacaine/methylprednisolone solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine/methylprednisolone solution (22 ml) injected over 2 minutes with 15 degrees head-up tilt
Study: 2535284
Drug: Bupivacaine/methylprednisolone solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine/methylprednisolone solution (22 ml) injected over 2 minutes with 15 degrees head-down tilt
Study: 31614214
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBTI) - 6 sessions delivered via telephone
Study: 23063111
Drug: Multicomponent exercise
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent exercise training (90 min, twice a week for six months)
Study: 15124190
Drug: Sonographic assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonographic assessment of clubfoot during treatment
Study: 3296728
Drug: Pirmenol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirmenol (50 mg intravenous bolus followed by 2.5 mg/min infusion)
Study: 3296728
Drug: Lidocaine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (75 mg intravenous bolus followed by 3 mg/min infusion)
Study: 26647072
Drug: Treatment guidance
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment guidance based on continuous glucose monitoring (CGM) data
Study: 20973155
Drug: Oxycodone (OX)
Normalized name: OX BILE
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone (OX) 20 mg/d
Study: 20973155
Drug: Morphine (MO)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (MO) 30 mg/d
Study: 18540331
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tramadol extended-release capsules (T-long) administered in the morning
Study: 18540331
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tramadol extended-release capsules (T-long) administered in the evening
Study: 18540331
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tramadol extended-release capsules (T-long) administered in the morning and evening
Study: 15787899
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus weekly telephone contact by a diabetes nurse educator (DNE) for 6 months.
Study: 12736400
Drug: Daily iron-folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily iron-folate supplementation
Study: 12736400
Drug: Weekly iron-folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly iron-folate supplementation
Study: 11014412
Drug: IY-81149 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: IY-81149 10 mg
Study: 11014412
Drug: IY-81149 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: IY-81149 20 mg
Study: 11014412
Drug: IY-81149 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IY-81149 5 mg
Study: 8676802
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (HPD) 1.6 g/kg BW + Enalapril (ENAL) 10 mg/day
Study: 8676802
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (LPD) 0.8 g/kg BW
Study: 1450309
Drug: PCA device
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA device Prominject with fentanyl demand doses of 34 micrograms, lockout time of 1 min, no concurrent infusion
Study: 1450309
Drug: PCA device
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA device ODAC with fentanyl demand doses of 34.5 micrograms, lockout time of 5 min, fixed-rate infusion of 4 micrograms/h
Study: 1450309
Drug: PCA device
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA device Prominject with tail-dose, fixed-rate infusion of 17 mg/h for a maximum of 60 minutes following a valid demand
Study: 1450309
Drug: PCA device
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA device ODAC with adaptive-rate infusion starting with 4 micrograms/h, adapted to individual needs
Study: 6421429
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment with antibiotics
Study: 3555277
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral bisacodyl
Study: 23307845
Drug: EB/TBA (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: EB/TBA (14 mg estradiol benzoate and 100 mg trenbolone acetate)
Study: 23307845
Drug: EB (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: EB (14 mg estradiol benzoate)
Study: 23307845
Drug: TBA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBA (100 mg trenbolone acetate)
Study: 17070196
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg/d)
Study: 17070196
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) (100 mg/d)
Study: 12075708
Drug: Clear topical
Normalized name: Lyclear Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear topical ointment
Study: 12075708
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ointment)
Study: 9861383
Drug: Triclabendazole, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triclabendazole, 5 mg/kg once daily for 3 days
Study: 9861383
Drug: Triclabendazole, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triclabendazole, 10 mg/kg twice on one day
Study: 9861383
Drug: Triclabendazole, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triclabendazole, 10 mg/kg in a single dose
Study: 9861383
Drug: Praziquantel, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel, 25 mg/kg thrice daily for 3 days
Study: 9861383
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 10 mg/kg
Study: 2167564
Drug: smallpox vaccine
Normalized name: SMALLPOX VACCINE
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: smallpox vaccine
Study: 736080
Drug: Microdrops (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdrops (0.005 or 0.01 ml) of a mixture of 5% phenylephrine HCl and 0.5% tropicamide HCl
Study: 736080
Drug: Diluted solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted solutions (0.005 or 0.01 ml)
Study: 23208965
Drug: Hypocaloric commercial
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric commercial formula (Optisource®) - 1109.3 kcal/day, 166.4 g carbohydrates, 63 g proteins, 21.3 g lipids
Study: 20833591
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg once daily)